Trial intelligence / Profile preview

Dermal inflammatory challenge with imiquimod in healthy volunteers

2020-005595-35Phase 2Completed

Sponsor: Centre for Human Drug Research
Start: Jan 2021
Modality: Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of imiquimod in inflammation, sponsored by Centre for Human Drug Research. Primary endpoint: Complement factors in skin biopsies following imiquimod challenge. Started Jan 2021; status: completed.

Drugs

imiquimod

Conditions

inflammation

Beyond the preview

Go deeper on 2020-005595-35.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2020-005595-35.